Aldeyra Therapeutics receives Nasdaq notice for minimum bid price noncompliance
ALDX•Aldeyra Therapeutics received a Nasdaq notice after its shares traded below the $1 minimum bid price for 30 consecutive business days. It has until May 17, 2027, to regain compliance during an initial 180-day period.
1. Nasdaq compliance period
The notice, received November 17, 2026, does not immediately affect Aldeyra Therapeutics’ listing on the Nasdaq Capital Market. To regain compliance, the stock must close at or above $1 per share for at least 10 consecutive business days before May 17, 2027. Nasdaq may grant an additional 180 days if other listing requirements are met and the company gives written notice of its intent to cure the deficiency.




